The present invention provides a compound of Formula (I):or a pharmaceutically acceptable salt thereof； pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient； and methods for treating physiological disorders, particularly congestive heart failure, hypertension, diabetic nephropathy, or chronic kidney disease, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Jedinjenje, naznačeno time, što je to (E) -N-(5-((E) -3-fluoro-6H-dibenzo[b,e]oksepin-11-lidenmetil)-1-((R)-1-metil-2-morfolin-4-il-etil)-1,3-dihidro-benzoimidazol-2-liden)-urea, ili njena farmaceutski prihvatljiva so.Prijava sadrži još 6 patentnih zahteva.
